

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

75-091

CHEMISTRY REVIEW(S)

1. CHEMISTRY REVIEW NO. 5

2. ANDA # 75-091

3. NAME AND ADDRESS OF APPLICANT

Mylan Pharmaceuticals Inc.
Attention: Frank R. Sisto
781 Chestnut Ridge Road
P.O. Box 4310
Morgantown, WV 26504-4310

4. LEGAL BASIS FOR SUBMISSION

Approved Product Sinemet CR of Dupont Pharma is not covered by any exclusivity as per 16th Edition and the 11th Supplement thereto of the 'Orange Book'. Pursuant to Section 505(j)(2)(A)(vii) of the FD & C Act, Mylan certifies that in its opinion U.S. Patents 4,900,755 and 4,832,957 are invalid, unenforceable or will not be infringed by the manufacture, sale, use, offer for sale or importation of Carbidopa/Levidopa Extended release Tablets. Mylan will market this product upon approval of this application and resolution of any issues related to the above two patents. Both of these patents expire on June 16, 2006. Mylan has now resolved the legal issues.

5. SUPPLEMENT(s)
N/A

6. PROPRIETARY NAME
N/A

7. NONPROPRIETARY NAME
Carbidopa and Levidopa
Extended-release Tablets

8. SUPPLEMENT(s) PROVIDE(s) FOR
N/A

9. AMENDMENTS AND OTHER DATES:

Firm

Original Application Submission Date- 3/13/97
Patent Infringement, notice of filing- 6/25/97
Bio amendment - 1/23/98
Chemistry major amendment- 2/6/98
Bio amendment - 6/19/98

Bio Amendment with new dissolution specifications as requested by
7/23/98

Chemistry amendment 8/11/98
Amendment adding new strength - 12/31/98
Amendment - 9/8/99
Withdrawal of new strength - 9/13/99
Label amendment- 9/13/99
Label amendment- 9/13/99
Amendment- 9/15/99
Amendment- 9/15/99
Amendment- 9/23/99

FDA

Acceptable for Filing Dated March 14, 1997
Chemistry & labeling deficiency - 7/7/97
Correspondence from Bio - 12/12/97
Label approval summary - 5/18/98
Bio review completed - 6/30/98
Chemistry deficiency - 7/7/98

Telephone conversation by B. Arnwine- 7/14/98
Bio review faxed on- 7/9/98
TA granted- 2/26/99
Bio review new amendment- 2/24/99
Label deficiency- 9/14/99
T-con by K. Lee- 9/15/99
Minor amendment- 9/23/99

10. PHARMACOLOGICAL CATEGORY
Treatment of Parkinson's disease
which may follow injury to the
central nervous system by CO intoxication
and Manganese intoxication
11. Rx or OTC
Rx
12. RELATED IND/NDA/DMF(s)
NDA #19-856 (CR)
ANDA #73-586 (IR)
ANDA #73-587 (IR)
See DMF Section (37)
13. DOSAGE FORM
Extended-release Tablet
14. POTENCY
50 mg/200 mg
15. CHEMICAL NAME AND STRUCTURE
Carbidopa
 $C_{10}H_{14}N_2O_4 \cdot H_2O$ Mole.wt 244.25 (-) - L-alpha-hydrazino-alpha-methyl-
beta-(3,4-dihydroxybenzene)propanoic acid monohydrate
CAS # 38821-49-7
Levodopa
 $C_9H_{11}NO_4$ Mole.wt 197.2 (-) - L-alpha-amino-beta-(3,4-
dihydroxybenzene) propanoic acid
CAS # 59-92-7
16. RECORDS AND REPORTS
N/A
17. COMMENTS
Method validation completed.
Bio and label review satisfactory.
EER Acceptable as of 12/21/98.
18. CONCLUSIONS AND RECOMMENDATIONS
Approval recommended.
19. REVIEWER:
Radhika Rajagopalan, Ph.D.
- DATE COMPLETED:
September 27, 1999

Radhika Rajagopalan

9/28/99

Page (s) 3

Contain Trade Secret,
Commercial/Confidential
Information and are not
releasable.

Chem Rev 5

9/28/99